Teva Says Omacetaxine Mepesuccinate Shows Activity in CML
Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.